Paradigm Asset Management Co. LLC Takes $1.26 Million Position in Hologic, Inc. $HOLX

Paradigm Asset Management Co. LLC acquired a new position in Hologic, Inc. (NASDAQ:HOLX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 19,300 shares of the medical equipment provider’s stock, valued at approximately $1,258,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Victory Capital Management Inc. grew its position in Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock worth $408,283,000 after buying an additional 1,692,177 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock worth $298,655,000 after purchasing an additional 764,573 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Hologic by 1.6% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock worth $276,303,000 after purchasing an additional 69,878 shares during the period. Ameriprise Financial Inc. lifted its position in Hologic by 0.8% during the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider’s stock worth $216,973,000 after purchasing an additional 29,133 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Hologic by 8.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider’s stock worth $175,331,000 after buying an additional 213,366 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Down 0.1%

Shares of NASDAQ:HOLX opened at $74.10 on Friday. The business’s 50-day moving average is $68.99 and its 200-day moving average is $65.11. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $80.31. The company has a market capitalization of $16.48 billion, a price-to-earnings ratio of 30.75, a P/E/G ratio of 2.54 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.03. The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. Hologic’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.01 earnings per share. Equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the transaction, the director owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their position. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently issued reports on HOLX. UBS Group increased their price target on shares of Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, July 31st. BTIG Research reiterated a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Argus raised their price objective on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Evercore ISI set a $78.00 target price on shares of Hologic and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Finally, Needham & Company LLC restated a “hold” rating on shares of Hologic in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $79.23.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.